Wednesday, May 6, 2020

In an op-ed published in the Financial Post, May 5, lawyer and adjunct professor Richard C. Owens, writes on why Canada’s drug discovery system seems broken. 

"Firms are supposed to maximize shareholder value. Nothing more. It is difficult to see how these firms’ decisions do that, at least in the short term. The cause for their apparently paradoxical behaviour may be rooted in the politics of defending the intellectual property system we rely on for drug discovery in societies that are increasingly hostile to private enterprise."

Read the full op-ed at the Financial Post